TY - JOUR
AU1 - Horiike, Norio
AU2 - Onji, Morikazu
AB - J Gastroenterol 2003; 38:302–304 Editorial Combination therapy with interferon-α and ribavirin as immunomodulators in patients with chronic hepatitis C Article on page 254 Immunological predictors of different responses to combination therapy with interferon α and ribavirin in patients with chronic hepatitis C Amaraa R, Mareckova H, Urbanek P, et al. Hepatitis C virus (HCV) infection is a worldwide health the function of DC, as we reported from in-vitro problem. Chronic hepatitis C (CHC) may progress to studies. liver cirrhosis or hepatocellular carcinoma over the Interferon therapy has become a common treatment 1 7 course of 20 to 30 years. for patients with CHC. However, a sustained virologi- For innate immunity against HCV, natural killer cal response (SVR) is achieved in only about 30%–40% (NK) cells are activated to kill the HCV-infected of patients by IFN. In addition, an SVR is achieved in hepatocytes. In addition, interferon (IFN), produced in very few patients with genotype 1b and a high viral load. HCV-infected hepatocytes and IFN-producing cells, Viral predictive markers of SVR as a result of IFN suppresses HCV replication. Dendritic cells (DC) acti- treatment are viral load, HCV genotype, and viral mu- vate NK cells and natural killer T (NKT) 
TI - Combination therapy with interferon-α and ribavirin as immunomodulators in patients with chronic hepatitis C
JF - Journal of Gastroenterology
DO - 10.1007/s005350300054
DA - 2003-03-01
UR - https://www.deepdyve.com/lp/springer-journals/combination-therapy-with-interferon-and-ribavirin-as-immunomodulators-qySqxzHIVu
SP - 302
EP - 304
VL - 38
IS - 3
DP - DeepDyve
ER -